RSC announces six London transfers for 2016
The Royal Shakespeare Company will transfer six shows to London later this year, including Gregory Doran’s King Lear.
The Alchemist and Doctor Faustus will transfer directly from the Swan Theatre in Stratford-upon-Avon to the Barbican – the RSC’s London home until 2020.
The two productions, directed by Polly Findlay and Maria Aberg respectively, will run in repertoire at the Barbican in September with the same casts as in Stratford.
RSC artistic director Doran’s production of King Lear, starring Antony Sher, will then run at the Barbican at the end of October, running alongside Cymbeline, directed by Melly Still.
In addition to the shows at the Barbican, the RSC productions of Love’s Labour’s Lost and Much Ado About Nothing (Love’s Labour’s Won) – which first ran in Stratford in 2014 – will be staged at the Theatre Royal Haymarket over Christmas.
They will run from December 9 to March 18, 2017, and follow stagings at Chichester Festival Theatre.
The two productions are directed by Christopher Luscombe and will see Edward Bennett reprise his roles as Berowne and Benedick.
RSC executive director Catherine Mallyon said she was “thrilled” that the RSC would have a strong presence in London in 2016, and added: “Our work in the wonderful Swan Theatre has often missed out in transfers, so I am glad that Maria Aberg’s Faustus and Polly Findlay’s Alchemist will play at the Barbican, along with our two epic Shakespeare plays Cymbeline and King Lear.”
We need your help…
When you subscribe to The Stage, you’re investing in our journalism. And our journalism is invested in supporting theatre and the performing arts.
The Stage is a family business, operated by the same family since we were founded in 1880. We do not receive government funding. We are not owned by a large corporation. Our editorial is not dictated by ticket sales.
We are fully independent, but this means we rely on revenue from readers to survive.
Help us continue to report on great work across the UK, champion new talent and keep up our investigative journalism that holds the powerful to account. Your subscription helps ensure our journalism can continue.